Current Drug Targets - Infectious Disorders

Rational Drug Design of DNA Oligonucleotides as HIV Inhibitors
pp. 79-90(14)
Authors: Jing N.; xu X.

Lipopolysaccharide as a Target for the Development of Novel Therapeutics in Gram-Negative Bacteria
pp. 91-106(18)
Authors: yethon J.A.; whitfield C.

Unexploited Viral and Host Targets for the Treatment of Human Immunodeficiency Virus Type 1 Infection
pp. 107-123(17)
Author: Garvey E.P.

The Emerging New Generation of Antibiotic: Ketolides
pp. 125-131(8)
Authors: zhong P.; shortridge V.

HIV-1 Integration as a Target for Antiretroviral Therapy: A Review
pp. 133-149(18)
Authors: pluymers W.; Clercq E.De; Debyser Z.

The HCMV Chemokine Receptor US28 is a Potential Target in Vascular Disease
pp. 151-158(8)
Authors: Streblow D.N.; Orloff S.L.; Nelson J.A.

1,3-beta-Glucan Synthase: A Useful Target for Antifungal Drugs
pp. 159-169(12)
Authors: Liu J.; Balasubramanian M.K.

Adhesion Mechanisms of the Lyme Disease Spirochete, Borrelia burgdorferi
pp. 171-179(9)
Author: coburn J.

The Discovery of Linezolid, the First Oxazolidinone Antibacterial Agent
pp. 181-199(20)
Authors: Ford C.W.; Zurenko G.E.; Barbachyn M.R.

E. Coli MurG: A Paradigm for a Superfamily of Glycosyltransferases
pp. 201-213(14)
Authors: Ha S.; Gross B.; walker S.

Overcoming Bacterial Resistance by Dual Target Inhibition: The Case of Streptogramins
pp. 215-225(11)
Authors: Canu A.; Leclercq R.

Antifibrogenic Therapies in Chronic HCV Infection
pp. 227-240(15)
Author: shimizu I.